Fiche publication
Date publication
décembre 2017
Journal
Biochemical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROHR Olivier
Tous les auteurs :
Schwartz C, Bouchat S, Marban C, Gautier V, Van Lint C, Rohr O, Le Douce V
Lien Pubmed
Résumé
Introduction of cART in 1996 has drastically increased the life expectancy of people living with HIV-1. However, this treatment has not allowed cure as cessation of cART is associated with a rapid viral rebound. The main barrier to the eradication of the virus is related to the persistence of latent HIV reservoirs. Evidence is now accumulating that purging the HIV-1 reservoir might lead to a cure or a remission. The most studied strategy is the so called "shock and kill" therapy. This strategy is based on reactivation of dormant viruses from the latently-infected reservoirs (the shock) followed by the eradication of the reservoirs (the kill). This review focuses mainly on the recent advances made in the "shock and kill" therapy. We believe that a cure or a remission will come from combinatorial approaches i.e. combination of drugs to reactivate the dormant virus from all the reservoirs including the one located in sanctuaries, and combination of strategies boosting the immune system. Alternative strategies based on cell and gene therapy or based in inducing deep latency, which are evoked in this review reinforce the idea that at least a remission is attainable.
Mots clés
5-AzadC (Pubmed CID: 451668), BIX 01294 (Pubmed CID: 25150857), Bryostatin (Pubmed CID: 5280757), Chaetocin (Pubmed CID: 11657687), Cure, Ingenol B (Pubmed CID: 44369392), JQ1 (Pubmed CID: 46907787), Latency, Panabinostat (Pubmed CID: 6918837), Prostratin (Pubmed CID: 454217), Remission, Reservoirs, Rituximab (Pubmed CID: 24801580), Romidepsin (Pubmed CID: 5352062), Shock and kill, Valproic acid (Pubmed CID: 3121), Vorinostat (Pubmed CID: 5311)
Référence
Biochem. Pharmacol.. 2017 12 15;146:10-22
